Moreover, anti-BP180 auto-antibodies in the sera of melanoma patients have been reported to be significantly higher than in the sera of healthy, at both early and advanced stages of disease, and this correlates with a higher probability for these patients to develop BP during anti-PD1 therapy (101). Here, COL17A1 is linked to melanoma.